


Supplementary Table. Demographic and biomarker profiles of patients with pemphigus vulgaris before therapy

Patient Characteristics	N (%)	Mean±SD or Median (IQR)	Range
Age	60 (100)	43.8±14.2	23–90
Sex			
Male	32 (53.3%)	-	-
Female	28 (46.7%)		
PDAI			
Cutaneous	6 (10)	17.5±16	4–43
Mucosal	12 (20)	30.17±16.22	10–62
Mucocutaneous	42 (70)	36.31±18.56	4–74
Total	60 (100)	33.57±17.56	4–74
Biomarkers			
Anti-Dsg1	60 (100)	116.9 (181.9) RU/mL	2.8–200
Anti-Dsg3	60 (100)	200 (93.6) RU/mL	40.2–200
IIF	60 (100)	320 (2400)	0–5120
CRP	60 (100)	2.1 (6.79) mg/L	0.2–82.3
Prolactin	60 (100)	9.91 (10.07) ng/mL	3.6–69.2
MIF	60 (100)	1.4 (1.06) pg/mL	0.05–3.2

IQR, interquartile range; Dsg, desmoglein; IIF, indirect immunofluorescence; CRP, C-reactive protein; MIF: macrophage migration inhibitory factor; PDAI, Pemphigus Disease Area Index



Supplementary Figure. Change in the meanrank of biomarkers over the follow-up period. A) Trend of standard biomarkers (Dsg1, Dsg3, and IIF) and CRP in 50 patients with PV treated with conventional therapy during the study period. B) Trend of standard biomarkers (Dsg1, Dsg3, and IIF) and CRP in 9 patients with PV treated with rituximab during the study period. The x-axis represents the follow-up time (1, before therapy; 2, one month after therapy; and 3, three months after therapy). The y-axis represents the mean rank of the biomarkers.